Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | BRD1 | O95696 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381965 | 0.89 | SCN1A (0.49) | PIK3C3SCN1ASCN5ASCN8ASMN1; SMN2 | |
| SCHEMBL1381446 | 0.81 | PIK3C3 (0.54) | PIK3C3MCL1MEP1BL3MBTL1SMN1; SMN2 | |
| SCHEMBL1379711 | 0.81 | MEP1B (0.43) | PIK3C3MCL1SCN1ASCN5ASCN8A | |
| SCHEMBL3922924 | 0.76 | SMN1; SMN2 (0.65) | MCL1L3MBTL1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4504840 | 0.73 | BRD4 (0.45) | MCL1MEP1BSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4513103 | 0.73 | SLC22A12 (0.47) | MCL1MEP1BL3MBTL1LMNAMAPT | |
| SCHEMBL3926949 | 0.72 | ABL1 (0.49) | MCL1MEP1BL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4505859 | 0.72 | BRD4 (0.47) | MCL1MEP1BSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL3937432 | 0.72 | SMN1; SMN2 (0.47) | MCL1MEP1BL3MBTL1SMN1; SMN2BRD4 | |
| SCHEMBL1378609 | 0.71 | HSD11B1 (0.59) | L3MBTL1SMN1; SMN2ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4809339-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-1763517-B1 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-05-11 | — | — | EP | claimed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | claimed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | claimed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | claimed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | claimed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | claimed |
| EP-1763517-B1 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010121814-A1 | PHARMACEUTICAL COMPOSITION, COMPRISING A STEROID-DEHYDROGENASE-REDUCTASE INHIBITOR, AND A MINERALOCORTICOID RECEPTOR ANTAGONIST | ONTOCHEM GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | HSD11B1, HSD17B1, HSD3B1 | PIK3C3 4103/4885MCL1 4497/4885SCN1A 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.